Reuters logo
in 3 months
BRIEF-Proteon Therapeutics announces increase to enrollment of ongoing phase 3 Patency-2 clinical trial
May 2, 2017 / 9:48 PM / in 3 months

BRIEF-Proteon Therapeutics announces increase to enrollment of ongoing phase 3 Patency-2 clinical trial

1 Min Read

May 2 (Reuters) - Proteon Therapeutics Inc

* Proteon Therapeutics announces increase to enrollment of ongoing phase 3 Patency-2 clinical trial

* Proteon Therapeutics Inc - Will increase planned enrollment of its ongoing phase 3 Patency-2 trial to 600 patients

* Proteon Therapeutics Inc- Increase in sample size does not alter study endpoints, which use same definitions as in Patency-1 trial

* Proteon - Increased sample size follows review of statistical plan, which revealed calculation error that overstated trial's power for secondary patency

* Proteon Therapeutics Inc says still expects to submit a biologics license application (BLA) to U.S. Food and Drug Administration (FDA) in 2019.

* Expects to complete enrollment in Q1 of 2018 for phase 3 Patency-2 trial and to report top-line data in Q1 of 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below